

Notice of Allowability

Application No.

09/823,214

Examiner

Russell Frejd

Applicant(s)

DUNLAVEY ET AL.

Art Unit

2128

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to applicant's telephone authorization on 21-June-2005.
2. ☒ The allowed claim(s) is/are 1-26.
3. ☒ The drawings filed on 30 March 2001 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 3.24.05
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____

Russell Frejd
RUSSELL FREJD
PRIMARY EXAMINER

In re Application of: Dunlavey et al.

Allowance of Application # 09/823,214

1. The following communication is in response to applicant's remarks received 24-March-2005.

Examiner's Amendment

2. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee. Authorization for this Examiner's Amendment was given by Kent Tobin (Reg. No. 39,496) on 20 and 21-June-2005.

2.1 In the Specification:

- | | | |
|---------|---------|------------------------------------------------------------------------------------------------------------------------|
| page 3 | line 10 | Delete "See http://www.hps-inc.com/edu/stella/stella.htm ." |
| page 43 | line 13 | Delete "Appendix, which is a copy of the". |

In the Claims:

- | | | |
|----------|--------|---------------------------------------------------------|
| claim 1 | line 1 | Change "A method" to --A computer-implemented method--. |
| claim 5 | line 1 | Change "A method" to --A computer-implemented method--. |
| claim 17 | line 6 | Change "(b;" to --(b);--. |

In re Application of: Dunlavey et al.

Reasons for Allowance

3. The following is an Examiner's Statement of Reasons for the indication of allowable subject matter. The instant application is directed to a non-obvious improvement over the invention described in the related prior art, specifically the article by van Meurs et al., entitled *Pharmacokinetic-Pharmacodynamic Model for Educational Simulations*, the improvement comprising a system and method for employing a computer-presented graphical user interface through which a user can construct a graphical pharmacological computational model, wherein objects representing one or both of pharmacokinetic and pharmacodynamic elements are connected via instructions from the graphical user interface, and converted into an internal format representing statements for the computational model under construction, whereby equations corresponding to the pharmacokinetic and pharmacodynamic elements logical computational model are derived from the statements, and actively displayed to the user. This patentable distinction is included in each of the independent claims, nos. 1, 5, 14, 16 and 21. The art of record, either individually or in combination, fails to teach, suggest, or render obvious the useful, concrete and tangible <pharmacological computational model construction> having the corresponding structure which is disclosed in the specification and equivalents thereof at least at page 7, line 2 through page 72, line 24, and Figures 1-8. In view of the foregoing, the claims of the present application are found to be patentable over the prior art.

Response Guidelines

4. Any comments considered necessary by applicant **MUST** be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably accompany the Issue Fee. Such submissions should clearly be labeled "Comments on Statement of Reasons for Allowance".

In re Application of: Dunlavey et al.

4.1 Any response to the Examiner in regard to this allowance should be


directed to: Russell Frejd, telephone number (571) 272-3779, Monday-Friday from 0530 to 1400 ET, or the examiner's supervisor, Jean Homere, telephone number (571) 272-3780. Inquires of a general nature or relating to the status of this application should be directed to the TC2100 Group Receptionist (571) 272-2100.

mailed to: Commissioner of Patents and Trademarks
P.O. Box 1450, Alexandria, VA 22313-1450

or faxed to: (703) 872-9306

Hand-delivered responses should be brought to the Customer Service Window, Randolph Building, 401 Dulany Street, Alexandria, VA, 22314.

Date: 21-June-2005

A handwritten signature in black ink, reading "RUSSELL FREJD", is written over a horizontal line.

**RUSSELL FREJD
PRIMARY EXAMINER**